Search results
Showing 706 to 720 of 1773 results for patient safety
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Insertion of an annular disc implant at lumbar discectomy (HTG358)
Evidence-based recommendations on insertion of an annular disc implant at lumbar discectomy. This involves inserting an implant to close the hole that is left in a torn disc after any bulging material has been removed during surgery.
View recommendations for HTG358Show all sections
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
In development Reference number: GID-TA11386 Expected publication date: TBC
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum. This involves opening up the closed pulmonary valve of the babies heart while it is still in the womb using a balloon-like device.
View recommendations for HTG114Show all sections
Sections for HTG114
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
A range of resources to help healthcare professionals effectively apply NICE guidance to enhance patient care and streamline clinical practices.
Evidence-based recommendations on endovascular closure of patent ductus arteriosus. This involves placing a blocking device into the heart, which stays in place permanently and the body’s tissue grows around it.
View recommendations for HTG59Show all sections
Sections for HTG59
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)
Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.
View recommendations for HTG244Show all sections
Sections for HTG244
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]
In development Reference number: GID-TA11333 Expected publication date: TBC